BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30415866)

  • 21. How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules.
    Roychoudhury S; Klein M; Souza F; Gimenez C; Laser A; Shaheen Cocker R; Chau K; Das K
    Diagn Cytopathol; 2017 Apr; 45(4):308-311. PubMed ID: 28188700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.
    Duick DS; Klopper JP; Diggans JC; Friedman L; Kennedy GC; Lanman RB; McIver B
    Thyroid; 2012 Oct; 22(10):996-1001. PubMed ID: 22873825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of malignancy in patients with cytologically suspicious thyroid nodules.
    Castro MR; Espiritu RP; Bahn RS; Henry MR; Gharib H; Caraballo PJ; Morris JC
    Thyroid; 2011 Nov; 21(11):1191-8. PubMed ID: 22007937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of strain ultrasound elastography versus fine-needle aspiration cytology for the differential diagnosis of thyroid nodules: a retrospective analysis.
    Yang X; Zhai D; Zhang T; Zhang S
    Clinics (Sao Paulo); 2020; 75():e1594. PubMed ID: 32578823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the ACR TI-RADS scoring allow us to safely avoid unnecessary thyroid biopsy? single center analysis in a large cohort.
    Koseoglu Atilla FD; Ozgen Saydam B; Erarslan NA; Diniz Unlu AG; Yilmaz Yasar H; Ozer M; Akinci B
    Endocrine; 2018 Sep; 61(3):398-402. PubMed ID: 29744655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examining the Role of Preoperative Positron Emission Tomography/Computerized Tomography in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.
    Merten MM; Castro MR; Zhang J; Durski J; Ryder M
    Thyroid; 2017 Jan; 27(1):95-102. PubMed ID: 27762671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 30. A Multicenter Prospective Validation Study for the Korean Thyroid Imaging Reporting and Data System in Patients with Thyroid Nodules.
    Ha EJ; Moon WJ; Na DG; Lee YH; Choi N; Kim SJ; Kim JK
    Korean J Radiol; 2016; 17(5):811-21. PubMed ID: 27587972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of cancer and the benign call rate of afirma gene classifier in
    Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
    Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
    Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
    Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 35. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
    Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 37. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules.
    Jug R; Parajuli S; Ahmadi S; Jiang XS
    Endocr Pathol; 2019 Jun; 30(2):134-137. PubMed ID: 30825100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the Bethesda System.
    Moon HJ; Kim EK; Yoon JH; Kwak JY
    Radiology; 2015 Jan; 274(1):287-95. PubMed ID: 25133852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome.
    Chaudhary S; Hou Y; Shen R; Hooda S; Li Z
    Acta Cytol; 2016; 60(3):205-10. PubMed ID: 27344463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.